Sandgaard reiterated confidence in the NiCO pulse oximeter, with FDA approval anticipated within six months of submission. He projected commercialization and revenue generation to begin in 2026. Q1 ...

Q1 2025 Earnings Conference Call April 29, 2025 4:15 PM ETCompany ParticipantsBrian Prenoveau - IRThomas Sandgaard - ...

Zynex, Inc. , an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, rehabilitation, and patient monitoring, today ...